Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Rick Strange who wrote (1386)	10/11/1998 1:20:00 AM
From: yosi s	Respond to of 1491

There were some studies that were monitored, which due to efficacy shown were halted in the middle and were approved. It would be very intresting to see te results of the last cohort of phase 2, now on going, if it continue with the same then it will be very intresting. as the severly affected patients outcome was bordering significant numbers. and by adding 20 more patients thing will be more evident. and easy going into phase 3.It will almost be a formality. (though it still has to take place.)

To: Rick Strange who wrote (1386)	10/12/1998 12:20:00 AM
From: Ariella	Read Replies (2) \| Respond to of 1491

Dear Rick -- The Orphan Drug Act defines orphan products as ones used to treat diseases or conditions affecting fewer than 200,000 persons in the United States. Such small patient populations reduce profit potential for sponsors, so the act grants special privileges and marketing incentives. <-- see quoted material fda.gov If we so tightly defined the target audience of HU-211 to fit this category, we would slice away much of the eps growth projected for the company in 3 to 5 years.